Structure via PubChem · Public domain (PubChem)
zaleplon
Sign in to saveAlso known as CL-284846, LJC-10846, Sonata®, ZAL-846, 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470635467
- Drug.imageL
- Zaleplon skeletal.svg
- Drug.image_classL
- skin-invert-image
- Drug.widthL
- 110
- Drug.imageR
- Zaleplon-from-xtal-Mercury-3D-bs.png
- Drug.image_classR
- bg-transparent
- Drug.widthR
- 180
- Drug.tradename
- Sonata, others
- Drug.MedlinePlus
- a601251
- Drug.DailyMedID
- Zaleplon
- Drug.addiction_liability
- Moderate
- Drug.routes_of_administration
- By mouth
- Drug.class
- nonbenzodiazepine
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- CF03
- Drug.legal_BR
- B1
- Drug.legal_NZ
- Not available in NZ
via Wikipedia infobox
Chemical data
- Formula
- C17H15N5O
- Molecular weight
- 305.33 g/mol
- IUPAC name
- N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
- SMILES
- CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
- InChIKey
- HUNXMJYCHXQEGX-UHFFFAOYSA-N
- XLogP
- 1
- Polar surface area
- 74.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1999
- Admin. routes
- oral
- Indications
- insomnia, anxiety, Dementia, depressive disorder
via ChEMBL · EBI
Research
486 papers- Zaleplon.2012
- Zaleplon.2006
- Zaleplon.2026
- Zaleplon: a review of its use in the treatment of insomnia.Drugs · 2000
- Insomnia Management: A Review and Update.The Journal of family practice · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 305.12766
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₇H₁₅N₅O
- medical condition treated
- insomnia
- canonical SMILES
- CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
- World Health Organisation international non-proprietary name
- zaleplon
- Commons category
- Zaleplon
- defined daily dose
- 10
- legal status (medicine)
- boxed warning
Sources (7)
via Wikidata · CC0
~8 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Special populations
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Synthesis
- Society and culture
- Recreational use
- Aviation use
- Military use
- References
Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.
== Medical uses == Zaleplon is slightly effective in treating insomnia, primarily characterized by difficulty falling asleep. Zaleplon significantly reduces the time required to fall asleep by improving sleep latency and may therefore facilitate sleep induction rather than sleep maintenance. Due to its ultrashort elimination half-life, zaleplon may not be effective in reducing premature awakenings; however, it may be administered to alleviate middle-of-the-night awakenings. However, zaleplon has not been empirically shown to increase total sleep time.
Excerpted from Wikipedia’s “zaleplon” article, available under the CC BY-SA 4.0 licence.